Board of Directors

Ken Mills served as the founding President and Chief Executive Officer of REGENXBIO from 2009-2024, and is now Chairman of the Board of Directors. Mr. Mills led REGENXBIO’s initial public offering in 2015 and grew the company into a leading gene therapy biotech, with end-to-end capabilities including research and development, clinical, and manufacturing. With the Company’s proprietary NAV® Technology Platform, Mr. Mills transformed the landscape of AAV gene therapy.
Prior to REGENXBIO, Mr. Mills was the Chief Financial Officer and Vice President of Business Development at Meso Scale Diagnostics, a privately held life sciences company. There, he served as a member of the founding management team, and worked to establish the company operations and ongoing business strategy. In this position, Mr. Mills supervised all company activities, including direct management of corporate and business development, strategic planning, finance and accounting activities. Prior to Meso Scale Diagnostics, he was Director of Business Development for IGEN International, a medical diagnostics company. Mr. Mills received an S.B. in chemistry from the Massachusetts Institute of Technology.

Curran M. Simpson is the President and Chief Executive Officer and member of the Board of Directors at REGENXBIO. Mr. Simpson previously served as the Company’s Chief Operating Officer. In that role, he led key business functions including Research & Clinical Development, Corporate Strategy, Manufacturing & Quality, Regulatory, and Commercial Operations. Mr. Simpson joined REGENXBIO in 2015 with extensive leadership experience across biopharmaceutical operations and served as the Company’s Chief Technology and Operations Officer before becoming COO. Prior to joining REGENXBIO, he was the Regional Supply Chain Head for North America and Interim Chief Operating Officer at GlaxoSmithKline (GSK). Mr. Simpson earlier served as interim CEO of Human Genome Sciences (HGS), where he led the integration of HGS into GSK, and as Senior Vice President of Operations and Vice President of Manufacturing Operations at HGS. Prior to HGS, Mr. Simpson was Director of Manufacturing Sciences at Biogen. Earlier in his career, Mr. Simpson served in an overseas assignment at Novo-Nordisk Biochem in Denmark and in various senior development and engineer roles at Genentech, working on Herceptin and Avastin, among other roles. Mr. Simpson has an M.S. in surface and colloid science from Clarkson University and a B.S. in chemistry from the Clarkson College of Technology.

Mr. Tassé is Chief Executive Officer of DBV Technologies SA. Previously, Mr. Tassé was Chairman and Chief Executive Officer of Alcresta Therapeutics, Inc., as well as Chairman and Chief Executive Officer of Ikaria, Inc., prior to its acquisition by Mallinckrodt Pharmaceuticals. He has also held leadership roles at Baxter International Inc. and GlaxoSmithKline plc. Mr. Tassé earned a B.S. in biochemistry from the University of Montreal. He previously served as a director at Indivior PLC and as a director at Bellerophon Therapeutics, Inc. Mr. Tassé has previously been a member of the Healthcare Leadership Council, the Health Section Governing Board of the Biotechnology Innovation Organization (BIO) and the board of directors of the Pharmaceutical Research and Manufacturers of America (PhRMA).

Allan Fox is the founding partner of FOXKISER, a nationally recognized firm specializing in biomedical research and development, law and public policy. He has created and built numerous ventures in both the public and private sectors. Mr. Fox specializes in identifying business opportunities and improving competitive market position in highly regulated industries, particularly health care. Before forming FOXKISER, Mr. Fox established the Washington office of the law firm of Kaye, Scholer, Fierman, Hays & Handler. While in the public sector, he served as Chief of Staff and Chief Legislative Assistant to U.S. Senator Jacob K. Javits of New York. He also served as Chief Counsel to the U.S. Senate Health and Scientific Research Subcommittee, chaired by Senator Edward M. Kennedy. Mr. Fox was a Fellow in Law, Science and Medicine at Yale Law School where he received an LL.M. degree. Mr. Fox also holds a J.D. and B.A. from Temple University.

Dr. Karabelas has held a number of senior executive positions in major pharmaceutical companies, including Head of Healthcare and CEO of Worldwide Pharmaceuticals for Novartis AG, where he had full responsibility for Novartis Pharma and Ciba Vision, as well as strategic and operational leadership of R&D. Dr. Karabelas was also Executive Vice President of SmithKline Beecham with responsibility for U.S. and European operations, regulatory, and strategic marketing. Most recently, Dr. Karabelas has chaired the boards of several biopharmaceutical companies, including Human Genome Sciences, Inc., Vanda Pharmaceuticals, Inc., SkyePharma PLC and Polyphor, AG. He currently chairs the board of Inotek and is a venture partner at Apple Tree Partners. Dr. Karabelas holds a Ph.D. in Pharmacokinetics from the Massachusetts College of Pharmacy.

Dr. Bennett, a leading molecular genetics researcher, is the F.M. Kirby Emeritus Professor of Ophthalmology at the Perelman School of Medicine and previously served as director of the Center for Advanced Retinal and Ocular Therapeutics (CAROT) at the University of Pennsylvania. In addition, Dr. Bennett is a Senior Investigator at the Center for Cellular and Molecular Therapeutics and The Children’s Hospital of Philadelphia (CHOP). She also co-founded life science companies Spark Therapeutics (acquired by Roche), GenSight Biologics and Limelight Bio. Prior to the University of Pennsylvania, Dr. Bennett worked as an academic instructor at the Johns Hopkins University School of Medicine. In more than 25 years of academic research, Dr. Bennett has published or contributed to more than 120 peer-reviewed publications on gene therapy, including her pioneering work on gene therapy delivery of RPE65, which was foundational to the approval of Luxturna®. Dr. Bennett received her Ph.D. in Zoology and Cell Biology from the University of California, Berkley, and obtained an M.D.
from Harvard University. She also completed postdoctoral fellowships in Radiobiology and Environmental Health at the University of California, San Francisco, Human Genetics at Yale School of Medicine and Development Genetics at the Johns Hopkins University School of Medicine. She received her B.S. in Biology from Yale University.

Dr. Glucksmann currently serves as a director at Scenic Biotech BV and as President and CEO of Sensorium Therapeutics each a privately held biotechnology company. Previously, she was President and Chief Executive Officer at Cedilla Therapeutics and an Entrepreneur-in-Residence at Third Rock Ventures where she focused on company formation. Before that, she was a founding employee and the Chief Operating Officer at Editas Medicine. She was also a founding employee and Senior Vice President of research and business operations at Cerulean Pharma. She began her career at Millennium Pharmaceuticals as a research scientist and held roles of increasing responsibility, culminating in the role of Vice President of platform technology groups, prior to transitioning into a senior position in strategic program management and operations. Dr. Glucksmann earned her Ph.D. in Molecular Genetics and Cell Biology from the University of Chicago in 1989 and completed her postdoctoral fellowship at the Massachusetts Institute of Technology in 1993.

Mr. Migausky has more than 30 years of public company leadership and senior financial management experience. He currently serves on the Board of Directors of Immunovant, Inc. Mr.Migausky previously served as interim Chief Financial Officer for Ocular Therapeutix, Inc. He also served as Executive Vice President and Chief Financial Officer of Dyax Corp., a position he held from 2008 through the company’s acquisition by Shire in 2016. Earlier, he served as Chief Financial Officer of Wellstat Management Company and as Chief Financial Officer of IGEN International and BioVeris Corporation from 1986 through their acquisitions by F.Hoffman LaRoche in 2004 and 2007, respectively. Additionally, Mr. Migausky has served as a trustee at the Massachusetts Eye and Ear Institute since 2015. He previously served as a director at Hyperion Catalysis International and Dimension Therapeutics, Inc. Mr. Migausky obtained a B.S. from Boston College and an M.B.A. in Finance from Babson College.

Dr. Stump was most recently Executive Vice President, Research and Development at Human Genome Sciences, Inc. (HGS) and joined the company in 1999. Prior to joining HGS, he held roles of increasing responsibility at Genentech, Inc. from 1989 to 1999, most recently as Vice President, Clinical Research and Genentech Fellow. Prior to joining Genentech, Dr. Stump was an Associate Professor of Medicine and Biochemistry at the University of Vermont. He earned an A.B. from Earlham College and an M.D. at Indiana University, followed by residency and fellowship training in internal medicine, hematology, oncology and biochemistry at the University of Iowa. He is currently a member of the Board of Directors of MacroGenics, Inc. and a member of the Board of Trustees of Earlham College.

Ms. Zachary is the Executive Vice President and General Counsel of Merck. In this role, she serves as a legal advisor to Merck’s directors and executives, leads the company’s office of general counsel and sets the company’s global legal strategy. She is also responsible for the company’s compliance, global safety and environment, and global security functions. Prior to joining Merck, Ms. Zachary was a partner at the international law firm Covington & Burling, LLP. She practiced in the area of pharmaceutical and medical device regulatory law and advised a wide range of manufacturers and trade associations on compliance with government requirements for the development, manufacture and sale of their products. Prior to that, Ms. Zachary served as an Associate Chief Counsel for enforcement at the U.S. Food and Drug Administration and as a Special Assistant U.S. Attorney in the Civil Division of the U.S. Attorney’s Office for the District of Columbia. Ms. Zachary holds a B.S./B.A. in biology and chemistry from Arizona State University and a J.D. from Harvard Law School.